180 related articles for article (PubMed ID: 32629158)
1. Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
Maddah M; Mandegar MA; Dame K; Grafton F; Loewke K; Ribeiro AJS
J Pharmacol Toxicol Methods; 2020 Sep; 105():106895. PubMed ID: 32629158
[TBL] [Abstract][Full Text] [Related]
2. Continued exposure of anti-cancer drugs to human iPS cell-derived cardiomyocytes can unmask their cardiotoxic effects.
Sakamoto K; Sakatoku K; Sugimoto S; Iwasaki N; Sano Y; Yamaguchi M; Kurokawa J
J Pharmacol Sci; 2019 Aug; 140(4):345-349. PubMed ID: 31521491
[TBL] [Abstract][Full Text] [Related]
3. High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes.
Grimm FA; Iwata Y; Sirenko O; Bittner M; Rusyn I
Assay Drug Dev Technol; 2015 Nov; 13(9):529-46. PubMed ID: 26539751
[TBL] [Abstract][Full Text] [Related]
4. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
Rajasingh S; Isai DG; Samanta S; Zhou ZG; Dawn B; Kinsey WH; Czirok A; Rajasingh J
Acta Pharmacol Sin; 2018 Oct; 39(10):1590-1603. PubMed ID: 29620051
[TBL] [Abstract][Full Text] [Related]
5. Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.
Grafton F; Ho J; Ranjbarvaziri S; Farshidfar F; Budan A; Steltzer S; Maddah M; Loewke KE; Green K; Patel S; Hoey T; Mandegar MA
Elife; 2021 Aug; 10():. PubMed ID: 34338636
[TBL] [Abstract][Full Text] [Related]
6. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.
Csöbönyeiová M; Polák Š; Danišovič L
Can J Physiol Pharmacol; 2016 Jul; 94(7):687-94. PubMed ID: 27128322
[TBL] [Abstract][Full Text] [Related]
7. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
8. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
9. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
10. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
12. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
13. Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes.
Burnett SD; Blanchette AD; Grimm FA; House JS; Reif DM; Wright FA; Chiu WA; Rusyn I
Toxicol Appl Pharmacol; 2019 Oct; 381():114711. PubMed ID: 31425687
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
[TBL] [Abstract][Full Text] [Related]
15. Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.
Matsui T; Miyamoto K; Yamanaka K; Okai Y; Kaushik EP; Harada K; Wagoner M; Shinozawa T
Toxicol Appl Pharmacol; 2019 Nov; 383():114761. PubMed ID: 31533062
[TBL] [Abstract][Full Text] [Related]
16. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.
Oleaga C; Riu A; Rothemund S; Lavado A; McAleer CW; Long CJ; Persaud K; Narasimhan NS; Tran M; Roles J; Carmona-Moran CA; Sasserath T; Elbrecht DH; Kumanchik L; Bridges LR; Martin C; Schnepper MT; Ekman G; Jackson M; Wang YI; Note R; Langer J; Teissier S; Hickman JJ
Biomaterials; 2018 Nov; 182():176-190. PubMed ID: 30130706
[TBL] [Abstract][Full Text] [Related]
18. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
[TBL] [Abstract][Full Text] [Related]
19. Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.
Ovics P; Regev D; Baskin P; Davidor M; Shemer Y; Neeman S; Ben-Haim Y; Binah O
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023024
[No Abstract] [Full Text] [Related]
20. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
